Q1 INTERIM REPORT
January - March
2022
Presentation
CEO Håkan Lagerberg CFO Jenny Graflind
Q1 2022 Highlights
2 new acquisitions & Strong start of the year
New acquisitions - NaturVet & Innovet
Organic growth 7% - 2022 target 20%
New product launches from many brands
Several Expos in Europe and USA
Business development - Wide offering
Net sales (MSEK)
400
350
300
250 | 182% |
200 |
100
90
80
70
60
50
Operational
EBITDA (MSEK)
158%
150
100
50
134,0377,7
40
30
20
10
36,7 | 94,7 | |
27,4% | 24,9% | |
0
Q1 2021 | Q1 2022 |
-
Q1 2021 | Q1 2022 |
Key Performance Indicators
Q1 2022
Sales per region Q1
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Swedencare AB published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 06:47:02 UTC.